COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
12/05/2026
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug [...]
Lumexa Imaging Announces First Quarter 2026 Results
12/05/2026
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, [...]
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
12/05/2026
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and [...]
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial [...]
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
12/05/2026
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026
12/05/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026 Le lancement réussi de Genio aux États-Unis génère une croissance trimestrielle séquentielle de 25 % du chiffre [...]
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE [...]
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all [...]
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
12/05/2026
Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE [...]
Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
12/05/2026
Expansion across the Southeast and Mid-Atlantic includes entry into Pennsylvania through joint venture with University of Pittsburgh Medical Center (UPMC) RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging ( [...]
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
12/05/2026
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
12/05/2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month [...]
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
12/05/2026
Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT [...]
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced [...]
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
12/05/2026
BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the [...]
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
12/05/2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3% , versus 79.0% in Q1 2025. GAAP Operating [...]
DBV Technologies participera à la 4e édition de la conférence annuelle BioConnect Investor organisée par H.C. Wainwright au Nasdaq
12/05/2026
Châtillon, France, le 12 mai (22 :30 CEST) 2026 DBV Technologies participera à la 4e édition de la conférence annuelle BioConnect Investor organisée par H.C. Wainwright au Nasdaq DBV Technologies (Euronext : DBV – ISIN [...]
Lifecore Biomedical to Participate at CDMO Live Europe
12/05/2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]

Pages